Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 8/20 | 0.62 |
| ▸ | AVPR1A | P37288 | 7/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8559574 | 0.94 | AVPR1A (0.56) | AVPR2AVPR1A | |
| SCHEMBL8561578 | 0.89 | AVPR1A (0.55) | AVPR2AVPR1ANPC1RAB9A | |
| SCHEMBL8564983 | 0.89 | AVPR2 (0.56) | AVPR2AVPR1A | |
| SCHEMBL8556495 | 0.87 | AVPR2 (0.55) | AVPR2AVPR1A | |
| SCHEMBL8558657 | 0.87 | ACHE (0.54) | AVPR2AVPR1ANPC1RAB9A | |
| SCHEMBL8559404 | 0.87 | AVPR2 (0.49) | AVPR2AVPR1A | |
| SCHEMBL8559608 | 0.87 | AVPR2 (0.49) | AVPR2AVPR1A | |
| SCHEMBL8562180 | 0.82 | AVPR2 (0.72) | AVPR2AVPR1A | |
| SCHEMBL8563344 | 0.82 | AVPR2 (0.81) | AVPR2AVPR1A | |
| SCHEMBL7339339 | 0.82 | AVPR2 (0.69) | AVPR2AVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0640592-B1 | N-acylated tricyclic azaheterorings useful as vasopressin antagonists | AMERICAN CYANAMID CO (US) | 1998-12-30 | — | — | EP | disclosed |
| EP-0640592-A1 | N-acylated tricyclic azaheterorings useful as vasopressin antagonists | AMERICAN CYANAMID COMPANY (US) | 1995-03-01 | — | — | EP | disclosed |